Clinical trials · Georgia
Acute Leukemia clinical trials in Georgia
We’re tracking 62 recruiting acute leukemia studies with a site in Georgia — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Albany, GeorgiaAges 18–59 - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Atlanta, GeorgiaAges 18 years+ - NCT05429632RecruitingPhase 3
Mocravimod to prevent relapse after bone marrow transplant for AML
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
Atlanta, GeorgiaAges 18–75 - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Atlanta, GeorgiaAges 1–25 - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Atlanta, GeorgiaAges Up to 21 years - NCT05082519RecruitingPhase 2
Calorie reduction and activity to help chemo work in B-ALL
This Phase 2 study tests whether eating fewer calories and doing activity safely can make chemotherapy work better for children and young adults with newly diagnosed B-ALL. It aims to reduce chemo resistance, meaning help leukemia respond more strongly to treatment.
Atlanta, GeorgiaAges 10–25 - NCT05909059RecruitingPhase 2
CAR-T therapy for people with kidney function problems
This study tests a type of immune treatment (CAR-T) in people whose kidneys are not working well, using chemotherapy first to help the CAR-T work. It may help people with certain blood cancers who have reduced kidney function to still receive CAR-T therapy safely.
Atlanta, GeorgiaAges 18 years+ - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Augusta, GeorgiaAges 18 years+ - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Atlanta, GeorgiaAges 18 years+ - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Augusta, GeorgiaAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Atlanta, GeorgiaAges 18 years+ - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Atlanta, GeorgiaAges 18 years+
Acute Leukemia trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting acute leukemia studies listed above.
- Emory University · 6 studies
- Augusta University Medical Center · 3 studies
- Children's Healthcare of Atlanta · 3 studies
- Ascentage Investigative Site #1045
- Blood and Marrow Transplant Group of Georgia
- Caitlin Guzowski
- Memorial Health University Medical Center
- Phoebe Putney Memorial Hospital
What taking part in a acute leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Acute Leukemia trials in other states
Common questions
- Are there acute leukemia clinical trials in Georgia?
- Yes. We're currently tracking 62 recruiting acute leukemia studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute leukemia study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute leukemia studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.